Enrollment completed ahead of schedule, underscoring strong interest from patient community in a potential new therapeutic option On track to complete the 24-week treatment period and announce topline ...
Alzheimer's disease (AD) is the most common cause of dementia, which is a general term for memory loss and other cognitive ...
Phase IV data on vedolizumab (Entyvio) in Crohn's disease suggested ... in cirrhosis and liver cancer risk. (Gut) The ...
Mix Up Your Workouts: Strength training isn’t the only way to burn visceral fat. Research has found that three aerobic or ...
In October 2025, the U.S. Food and Drug Administration (FDA) granted approval to multiple new cancer therapies and supportive care options, covering treatments for acute myeloid leukemia (AML), ...
Cells convert mechanical forces into signals that influence physiological processes, such as exercise strengthening bones. A ...
Let’s accept it: if there are a few words that can shake up a conversation and lace it with concern, ‘cholesterol’ is one of ...
Dr. Bob Uslander launched TRUE Palliative Care, providing personalized in-home support for people with serious or chronic illness. SAN DIEGO, Oct. 28, 2025 / PRZen / Following California’s landmark ...
UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that KYGEVVI® has been granted approval by the U.S. Food and Drug Administration (FDA) for the treatment of adults and ...
Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to ...
Indulekha began learning dance at three, performed on stage at four, and entered films as a child artist at 13.
The FDA is said to be making a U-turn on uniQure’s one-time gene therapy candidate for Huntington’s disease despite the treatment being hailed as a game-changer. | FDA is said to be making a U-turn on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback